Studies in multiple animal models have shown that antibody-mediated Tim-3 inhibition enhances the activity of immune checkpoint blockade [66–68] although detailed analysis of the tumor immune landscape is still incomplete after Tim-3 inhibition. Here, HAVCR2 is linked to neoplasm.